The accompanying notes are an integral part of these condensed financial statements.
NOTES TO CONDENSED FINANCIAL STATEMENTS
For the Six Months' Period Ended June 30, 2021
(unaudited)
1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
MobileSmith, Inc. (referred to herein as the “Company,” “us,” “we,” or “our”) was incorporated as Smart Online, Inc. in the State of Delaware in 1993. The Company changed its name to MobileSmith, Inc. effective July 1, 2013. The same year the Company focused exclusively on development of do-it-yourself customer facing platform that enabled organizations to rapidly create, deploy, and manage custom, native smartphone and tablet apps deliverable across iOS and Android mobile platforms without writing a single line of code. During 2017 the Company concluded that it had its highest rate of success with clients within the Healthcare industry and concentrated its development and sales and marketing efforts in that industry. During 2018 we further refined our Healthcare offering and redefined our product - a suite of e-health mobile solutions that consist of a catalog of ready to deploy mobile app solutions (App Blueprints) and support services. In 2019 and 2020, we consolidated our current solutions under a single offering branded Peri™. Peri™ is a cloud-based collection of applications that run of our architected healthcare technology ecosystem. The architecture is designed to do the following:
●
|
improve experience of healthcare patients and consumers, who are often at the same time members of various medical insurance networks
|
●
|
optimize delivery of healthcare and relationship between members and insurance networks
|
●
|
increase adoption, utilization and intelligence of EMRs (electronic medical records), extend EMR's usability to patients and consumers of healthcare Peri™ is designed to bridge the gap between healthcare industry system tools and healthcare consumer's mobile device.
|
Our flagship PeriOp offering is an EMR integrated mobile app based set of pre- and postoperative instructions (which we refer to as Clinical Pathways), that establishes a direct two-way clinical procedure management process between a patient and a healthcare provider and by doing so improves patient engagement and procedural adherence.
The Company prepared the accompanying unaudited condensed financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its audited annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly present its financial position, results of operations, cash flows, and stockholders’ deficit as of June 30, 2021. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These condensed financial statements and accompanying notes should be read in conjunction with the audited annual financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 on file with the SEC (the “Annual Report”).
Except as otherwise noted, there have been no material changes to the Company’s significant accounting policies as compared to the significant accounting policies described in the Annual Report. The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the six months ended June 30, 2021, the Company incurred net losses as well as negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts or classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company’s continuation as a going concern depends upon its ability to generate sufficient cash flows to meet its obligations on a timely basis, to obtain additional financing as may be required, and ultimately to attain profitable operations and positive cash flows. Since November 2007, the Company has been funding its operations, in part, from the proceeds from the issuance of notes under a convertible secured subordinated note purchase agreement facility which was established in 2007 (the "2007 NPA"), and an unsecured convertible subordinated note purchase agreement facility established in 2014 (the "2014 NPA"), and subordinated promissory notes to related parties. In December of 2020 and January of 2021, we exchanged all our non-bank debt, including the debt issued under the 2007 NPA and the 2014 NPA, into Series A Convertible Preferred Stock (the "Series A Preferred Stock") with the same investors. We expect to finance our operations through the issuance of Series A Preferred Stock going forward. If financing through issuance of Series A Preferred Stock becomes unavailable, we will need to seek other sources of funding. As such, there is substantial doubt about the Company's ability to continue as a going concern.
Recently Issued Accounting Pronouncements and Their Impact on Significant Accounting Policies
The Company's significant accounting policies are detailed in "Note 2: Significant Accounting Policies" of the Company's Annual Report.
On August 5, 2020, the FASB issued ASU 2020-06 "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity" which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is not expected to have a material impact on the financial statements of the Company. For the Company the ASU is not effective until fiscal year 2024, but early adoption is permitted as early as current fiscal year ending December 31, 2021.
2. DEBT
The table below summarizes the Company's debt outstanding on June 30, 2021 and December 31, 2020:
Debt Description
|
|
June 30,
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
2021
|
|
|
2020
|
|
|
Maturity
|
|
Rate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comerica Bank Loan and Security Agreement
|
|
$
|
5,000,000
|
|
|
$
|
5,000,000
|
|
|
June, 2022
|
|
|
3.85
|
%
|
Second PPP Loan
|
|
|
542,000
|
|
|
|
-
|
|
|
February, 2026
|
|
|
1.00
|
%
|
First PPP Loan
|
|
|
-
|
|
|
|
542,100
|
|
|
April, 2022
|
|
|
1.00
|
%
|
Convertible notes, net of discount of $1,927,892 as of December 31, 2020
|
|
|
-
|
|
|
|
972,108
|
|
|
November, 2022
|
|
|
8.00
|
%
|
Total debt
|
|
|
5,542,000
|
|
|
|
6,514,208
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: current portion of long term debt
|
|
|
-
|
|
|
|
423,067
|
|
|
|
|
|
|
|
Debt - long term
|
|
$
|
5,542,000
|
|
|
$
|
6,091,141
|
|
|
|
|
|
|
|
Bank Loan
The Company has an outstanding Loan and Security Agreement with Comerica Bank ("Comerica") dated June 9, 2014 (the "LSA") in the amount of $5,000,000, with an extended maturity of June 9, 2022. The LSA is secured by an extended irrevocable letter of credit issued by UBS AG (Geneva, Switzerland) ("UBS AG") with a renewed term expiring on May 31, 2022, which term is renewable for one year periods, unless notice of non-renewal is given by UBS AG at least 45 days prior to the then current expiration date.
The LSA with Comerica has the following additional terms:
●
|
a variable interest rate at prime plus 0.6% payable quarterly;
|
●
|
secured by substantially all of the assets of the Company, including the Company’s intellectual property;
|
●
|
acceleration of payment of all amounts due thereunder upon the occurrence and continuation of certain events of default, including but not limited to, failure by the Company to perform its obligations, observe the covenants made by it under the LSA, failure to renew the UBS AG SBLC, and insolvency of the Company.
|
Convertible Notes and January 2021 Debt Exchange
On January 28, 2021 the Company exchanged its remaining unsecured Convertible Subordinated Notes (the “2014 NPA Notes”) under its existing unsecured Convertible Subordinated Note Purchase Agreement dated December 10, 2014 (the “2014 NPA”) for Series A Preferred Stock. The carrying value of 2014 NPA Notes of $1,075,713 consisting of face value of $2,900,000 net of unamortized discount of $1,849,773 plus accrued interest of $103,605 was exchanged for 70,014 shares of Series A Preferred Stock ("the January 2021 Debt Exchange"). The January 2021 Debt Exchange was accounted for as debt extinguishment and the newly issued shares of Series A Preferred Stock were recorded at fair value in accordance with ASC 470 "Debt". The issued shares were fair valued at $7,660,970. The difference between the carrying amount of extinguished debt and fair value of the Series A Preferred Stock issued resulted in loss recorded on the statement of operations of $6,507,137.
Second PPP Loan
On February 9 2021, the Company received $542,000 of proceeds from a note payable issued under either the Small Business Administration "the SBA" Paycheck Protection Program ("PPP") under section 7(a)(36) of the Small Business Act or the SBA's Paycheck Protection Program Second Draw Loans under Section 7(a)(37) of the Small Business Act. The note matures in five years and bears interest at 1% per year. Similar to the Company's initial PPP Loan, the second loan contains a loan forgiveness covered period of six months from the date of issuance in which the Company will not be obligated to make any payments of principal or interest. If the Company does not submit a loan forgiveness application within ten months after the end of the loan forgiveness covered period, the Company must begin making principal and interest after that period (the "Loan Forgiveness Application Submission Period"). Interest continues to accrue during the deferment period. If the Company is unable to or does not follow those guidelines for the loan to be forgiven by the SBA, the Company would be required to repay a portion of or the entire balance of the loan proceeds in full. If any portion of the loan is not forgiven, the Company may start making payments on, but not before February of 2022 - the end of the Loan Forgiveness Application Submission Period.
Forgiveness of First PPP Loan
On February 18, 2021 our first PPP Loan was forgiven by the SBA in its entirety. The forgiveness was accounted for as debt extinguishment which resulted in a gain of $542,100 recorded in our statement of operations.
3. COMMITMENTS AND CONTINGENCIES
Legal Proceedings
From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. In the opinion of management, no pending or known threatened claims, actions or proceedings against the Company are expected to have a material adverse effect on its financial position, results of operations or cash flows. However, the Company cannot predict with certainty the outcome or effect of any such litigation or investigatory matters or any other pending litigations or claims. There can be no assurance as to the ultimate outcome of any such lawsuits and investigations. The Company will record a liability when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company periodically evaluates developments in its legal matters that could affect the amount of liability that it has previously accrued, if any, and makes adjustments as appropriate. Significant judgment is required to determine both the likelihood of there being, and the estimated amount of, a loss related to such matters, and the Company’s judgment may be incorrect. The outcome of any proceeding is not determinable in advance. Until the final resolution of any such matters that the Company may be required to accrue for, there may be an exposure to loss in excess of the amount accrued, and such amounts could be material.
4. STOCKHOLDERS DEFICIT
Preferred Stock
On January 28, 2021 and as a result of the January 2021 Debt Exchange transaction the Company issued 70,014 shares of Series A Preferred Stock. On the date of the January 2021 Debt Exchange the market value of the common stock was above the Series A Preferred Stock conversion price of $1.43, which resulted in the conversion feature that was beneficial to the holder on the date of the exchange. The resulting beneficial conversion feature was recorded as a discount and amortized in its entirety as a deemed dividend on the date of the January 2021 Debt Exchange and charged to loss attributable to common shareholders on the Company's Statement of Operations in the amount of $3,507,701.
In addition, the Company issued 64,376 shares of Series A Preferred Stock in exchange for $2,761,700 in cash funding. The shares were issued with beneficial conversions feature discount and resulted in a deemed dividend with charge to loss attributable to common shareholders of $2,761,700.
Series A Preferred Stock with the following standard terms:
●
|
Each share of Series A Preferred Stock shall have a par value of $0.001 per share and a stated value equal to $42.90 (the "Stated Value ");
|
●
|
Each share of the Series A Preferred Stock then outstanding shall be entitled to receive an annual dividend equal to $3.43, subject to proration related to the timing of issuance. Such dividend is designed to have an effective yield of 8% on invested stated value;
|
●
|
Each dividend shall be paid either in shares of Series A Preferred Stock (“Payment-in-Kind”) or in cash, at the option of the Corporation, on the respective Dividend Date;
|
●
|
The Holders of Series A Preferred Stock shall have no voting rights with respect to any matters to be voted on by the stockholders of the Corporation;
|
●
|
The Holders of Series A Preferred Stock shall have certain Board observation and inspection rights administered through a designated Agent;
|
●
|
Each share of Series A Preferred Stock shall be convertible, at any time and from time to time, at the option of the Holder into 30 shares of Common Stock, which results in conversion ratio of $1.43 of stated value of Series A Preferred Stock into one share of common stock (the "Series A Preferred Conversion Price");
|
●
|
The shares are subject to automatic conversion immediately prior to the occurrence of a Fundamental Transaction, as defined in a Certificate of Designation. A Fundamental Transaction includes, but is not limited to, a sale, merger or similar change in ownership.
|
Equity Compensation Plan
The following is a summary of the stock option activity for the six months ended June 30, 2021:
|
|
Number of Shares
|
|
|
Weighted Average Exercise Price
|
|
|
Weighted Average Remaining Contractual Term
|
|
|
Aggregate Intrinsic Value
|
|
Outstanding, December 31, 2020
|
|
$
|
10,683,300
|
|
|
$
|
1.85
|
|
|
|
7.4
|
|
|
$
|
17,060,533
|
|
Cancelled
|
|
|
(902,500
|
)
|
|
|
1.57
|
|
|
|
|
|
|
|
|
|
Issued
|
|
|
1,475,000
|
|
|
|
3.10
|
|
|
|
|
|
|
|
|
|
Outstanding, June 30, 2021
|
|
$
|
11,255,800
|
|
|
|
2.04
|
|
|
|
7.9
|
|
|
|
21,752,184
|
|
Vested and exercisable, June 30, 2021
|
|
$
|
5,195,821
|
|
|
$
|
1.85
|
|
|
|
7.3
|
|
|
$
|
11,032,574
|
|
Aggregate intrinsic value represents the difference between the closing price of the Company’s common stock on June 30, 2021, and the exercise price of outstanding, in-the-money stock options. The closing price of the common stock on June 30, 2021, as reported on the OTCQB, was $3.50 per share.
On June 30, 2021, an amount of $11,495,025 unvested expense related to outstanding stock options has yet to be recorded over a weighted average period of 3.3 years.
5. FAIR VALUE MEASUREMENTS
We are required to provide financial statement users with information about assets and liabilities measured at fair value in the balance sheet or disclosed in the notes to the financial statements regarding (1) the valuation techniques and inputs used to develop fair value measurements, including the related judgments and assumptions made, (2) the uncertainty in the fair value measurements as of the reporting date, and (3) how changes in the measurements impact the performance and cash flows of the entity.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy prescribed by the accounting literature contains three levels as follows:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimations.
The January 2021 Debt Exchange resulted in transaction which required the Company to recognize debt extinguishment and to record newly issued financing instrument at fair value at the date of the transaction on a non-recurring basis. Fair value measurement was categorized as Level 3 fair value measurement due to use of various unobservable inputs to the pricing model. A single most significant factor included in pricing models was the Level 1 input of observable market value of MobileSmith common stock on the date of the transaction, as quoted on the OTCQB. Despite the thinly traded nature of the Company stock, the quoted market value could not be ignored in determination of fair value in the transaction.
The Company used the income approach to arrive at the fair value of the Series A Stock on January 28, 2021 - the date of the exchange. Using this approach the value of Series A Preferred Stock is equal to the present value of the cash flow streams that can be expected to be generated by the holder in a combination of dividends and conversion of preferred shares into common and subsequent sale of the common shares. The Company used the Monte Carlo model to simulate future movement of our common stock and discounted the results back to January 28, 2021 transaction date. The model used the following notable inputs:
●
|
the market price of the Company common stock on January 28, 2021 of $3.10 as a starting point of simulation
|
●
|
the risk free rate and discount rate of 1.35%;
|
●
|
term of simulation extended to 15 years;
|
●
|
the model also considered the probability of a Fundamental Transaction (as defined in Series A Preferred Stock certificate of designation) and probabilities of payment of dividend in cash or in additional preferred shares.
|
6. DISAGGREGATED PRESENTATION OF REVENUE AND OTHER RELEVANT INFORMATION
The tables below depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors, such as type of customer and type of contract.
Customer size impact on billings and revenue:
|
|
6 Months Ended June 30, 2021
|
|
|
6 Months Ended June 30, 2020
|
|
|
|
Billings
|
|
|
GAAP Revenue
|
|
|
Billings
|
|
|
GAAP Revenue
|
|
Top 5 Customers (Measured By Amounts Billed)
|
|
$
|
342,000
|
|
|
$
|
221,640
|
|
|
$
|
433,010
|
|
|
$
|
435,747
|
|
All Other Customers
|
|
$
|
501,543
|
|
|
$
|
594,703
|
|
|
$
|
615,259
|
|
|
$
|
796,597
|
|
|
|
$
|
843,543
|
|
|
$
|
816,343
|
|
|
$
|
1,048,269
|
|
|
$
|
1,232,344
|
|
For the six months ended June 30, 2021, three customers accounted for 70% of the accounts receivable balance and no customer accounted for more than 10% of total revenue.
For the six months ended June 30, 2020, four customers accounted for 74% of the accounts receivable balance and one customer accounted for 18% of total revenue.
Below is a summary of new customer acquisition impact on billings and revenue:
|
|
6 Months Ended June 30, 2021
|
|
|
6 Months Ended June 30, 2020
|
|
|
|
Billings
|
|
|
GAAP Revenue
|
|
|
Billings
|
|
|
GAAP Revenue
|
|
Customers In Existence As Of The Beginning Of The Period (Including Upgrades)
|
|
$
|
843,543
|
|
|
$
|
816,343
|
|
|
$
|
1,036,182
|
|
|
$
|
1,232,344
|
|
Customers Acquired During The Period
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
12,087
|
|
|
$
|
-
|
|
|
|
$
|
843,543
|
|
|
$
|
816,343
|
|
|
$
|
1,048,269
|
|
|
$
|
1,232,344
|
|
7. LEASES
Leases (Topic 842) Disclosures
We are a lessee for a non-cancellable operating lease for our corporate office in Raleigh, North Carolina. We are also a lessee for a non-cancellable finance lease for a corporate vehicle and office furniture. Financing leases are not significant in terms of both balances and period expenses. The operating lease for the corporate office expires on April 30, 2024.
The following table summarizes the information about our operating lease:
The following table summarizes the information about operating lease:
|
|
Six Months Ended June 30, 2021
|
|
Operating lease expense
|
|
$
|
102,863
|
|
Remaining Lease Term (Years)
|
|
2.7 years
|
|
Discount Rate
|
|
|
8
|
%
|
Maturities of operating lease liability as of June 30, 2021 were as follows:
|
|
Operating Lease Expense
|
|
|
Variable Lease Expense
|
|
|
Total Lease Expense
|
|
2021 (remaining 6 months)
|
|
$
|
95,537
|
|
|
$
|
6,843
|
|
|
$
|
102,380
|
|
2022
|
|
|
191,074
|
|
|
|
14,096
|
|
|
|
205,170
|
|
2023
|
|
|
191,074
|
|
|
|
14,519
|
|
|
|
205,593
|
|
2024
|
|
|
63,691
|
|
|
|
4,840
|
|
|
|
68,531
|
|
Total lease payments
|
|
$
|
541,376
|
|
|
$
|
40,298
|
|
|
|
581,674
|
|
Less imputed interest
|
|
|
|
|
|
|
|
|
|
|
(67,034
|
)
|
Total
|
|
|
|
|
|
|
|
|
|
$
|
514,640
|
|
8. SUBSEQUENT EVENTS
Subsequent to June 30, 2021 the Company granted approximately 760,000 of stock options to certain employees. The newly issued stock options replaced stock options previously expired unexercised. The newly issued stock options have an exercise price equal to the fair market price of $1.63 on the date of grant, 10-year term and 5-year vesting.